Core Viewpoint - The company, Gilead Sciences (01672), has seen its stock price increase by over 4%, currently trading at 11.68 HKD, with a trading volume of 8.54 million HKD. The rise is attributed to the announcement of the clinical development phase for two new combination drugs aimed at obesity treatment [1]. Group 1: Clinical Development - Gilead Sciences has announced that its next-generation amylin receptor agonist ASC36 and the next-generation GLP-1R/GIPR dual-target agonist ASC35 combination formulation have entered the clinical development stage [1]. - The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36 and ASC35 for obesity treatment in the second quarter of 2026 [1]. Group 2: Market Potential - The CEO, Dr. Wu Jinzi, expressed optimism that ASC36 and ASC35 combination formulations could achieve more significant weight loss effects in obese populations compared to monotherapy, based on encouraging preclinical data [1]. - The increasing results demonstrate the company's platform technology's capability in designing, optimizing, and developing multiple long-acting peptide injections administered monthly [1].
港股异动 | 歌礼制药(01672)再涨超4% ASC36和ASC35复方制剂进入临床开发阶段